TAVR in Aortic Regurgitation
TAVR is NOT currently indicated for patients with isolated severe aortic regurgitation according to established guidelines, though emerging evidence suggests it may be considered in highly selected, inoperable patients at experienced centers.
Guideline-Based Recommendations
The 2012 ACCF/AATS/SCAI/STS expert consensus explicitly states that TAVR is NOT currently recommended for patients with severe AR due to limited available information 1. The approved indication for TAVR is specifically for:
- Severe, symptomatic, calcific stenosis of a trileaflet aortic valve (not regurgitation)
- Patients with prohibitive or high surgical risk
- Suitable aortic and vascular anatomy
- Predicted survival >12 months
Why AR is Excluded from Standard TAVR Indications
The guidelines list "severe AR" under conditions where TAVR is not recommended because additional scientific data is needed to establish the risk/benefit ratio 1. The original TAVR devices were designed and tested for stenotic valves with calcification that provides anchoring support—a feature absent in pure regurgitant valves.
Current Clinical Reality (2023-2026)
More recent guidelines acknowledge evolving practice. The 2023 ACC/AHA and ESC/EACTS comparison notes that American guidelines do not recommend (Class III) TAVR in patients with isolated AR who are at low surgical risk 2. However, this implies consideration may exist for prohibitive-risk patients.
The 2022 systematic review confirms that TAVR should not be performed in patients with isolated severe AR who have indications for SAVR and are surgical candidates, but may be considered in experienced centers for selected patients ineligible for SAVR 3.
Emerging Evidence for Select Cases
Recent research (2024-2026) demonstrates TAVR feasibility in pure AR with:
- Device success rates: 74-100% 4
- 30-day mortality: 4.6% 4
- Moderate/severe post-procedural AR: only 1.02% 4
- Conversion to surgery: 0.59% 4
Critical Patient Selection Criteria
If considering TAVR for AR (off-label), patients must have:
- Prohibitive surgical risk (>50% mortality/irreversible morbidity at 30 days, frailty, porcelain aorta, prior radiation)
- Suitable anatomy for device anchoring despite lack of calcification
- Treatment at experienced centers with dedicated AR-TAVR expertise
- Heart team consensus including interventional and surgical specialists
Practical Algorithm
For patients with severe symptomatic AR:
First-line: Surgical AVR (Class I indication) 3
- Symptomatic severe AR with any LVEF
- Asymptomatic with LVEF <50% (or <55% per some guidelines)
- Asymptomatic with LVESD >50 mm
Consider TAVR only if:
- Patient is inoperable (not just high-risk, but truly prohibitive)
- Experienced center with AR-TAVR program exists
- Newer dedicated AR devices available (not standard TAVR valves)
- Patient understands off-label/investigational nature
Absolute contraindications to TAVR in AR:
- Low or intermediate surgical risk candidates
- Lack of experienced center
- Unsuitable anatomy for valve anchoring
Key Pitfalls to Avoid
- Do not use TAVR as routine alternative to surgery in AR—it remains investigational despite emerging data
- Beware of valve migration/embolization risk—pure AR lacks calcification for anchoring
- Higher paravalvular leak rates compared to TAVR for stenosis
- Permanent pacemaker rates remain significant (6.72% in recent data) 4
- Do not extrapolate TAVR-for-stenosis data to AR patients—completely different pathophysiology
Bottom Line
Surgical AVR remains the gold standard for aortic regurgitation across all risk categories. TAVR in pure AR is an evolving, off-label application reserved exclusively for inoperable patients treated at specialized centers with multidisciplinary expertise. The 2012 consensus guidelines remain the authoritative source, clearly stating TAVR is not recommended for AR [1-1], though compassionate use in truly inoperable cases at expert centers may be reasonable based on emerging evidence 4, 5.